January 2026
Second closing of our series A round
NanoPhoria announces the second closing of our series A round to include participation from the European Innovation Council.
About NanoPhoria
NanoPhoria is a preclinical-stage biotech company pioneering the next generation of cardiovascular treatments through an innovative inhaled, Nano-in-Micro delivery platform. Our mission is to transform the way therapeutic peptides and RNAs are delivered, enabling precise, tissue-directed treatment for complex cardiovascular conditions.
Our lead product, NP-MP1, is an inhalable Nano-in-Micro formulation delivering a first-in-class calcium channel modulator peptide for the treatment of Heart Failure with Reduced Ejection Fraction (HFrEF), which is a chronic syndrome impacting millions worldwide.
At the heart of our delivery technology is a proprietary Nano-in-Micro platform built on inorganic Calcium Phosphate nanoparticles (CaP) embedded in highly respirable microparticles. CaP nanoparticles represent a versatile, biomimetic nanocarrier that can be loaded or surface-decorated with novel therapeutics. This non-viral, scalable system is designed for inhalation and other administration routes, offering a safe and effective alternative for advanced drug delivery.
By combining cutting-edge nanotechnology with therapeutic innovation, NanoPhoria is redefining what’s possible in cardiovascular care.
TIMELINE
2026
December 2025
NanoPhoria Named Startup of the Year by StartupItalia
NanoPhoria was been named Startup of the Year by StartupItalia at SIOS25 Winter, the tenth anniversary edition of the StartupItalia Open Summit.
October 2025
NanoPhoria secures €83.5m Italian Series A Biotech
NanoPhoria sets the record for the largest ever Italian Series A Biotech raise, securing €83.5m. The round was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with Panakès Partners participating.
February 2025
NanoPhoria awarded €17.5m
NanoPhoria awarded €17.5m by the European Innovation Council’s Accelerator Program, making it the only Italian biotech to receive such an award.
2025
January 2024
New non-executive members to the Board of Directors
Dr Suman Shirodkar as chair and Prof. Michael Davidson as non-executive member of our Board of Directors
January 2024
NanoPhoria publishes milestone paper in the Journal of American College of Cardiology
NanoPhoria publishes milestone paper in the peer-reviewed Journal of American College of Cardiology, demonstrating NP-MP1’s ability to improve ejection fraction by 17% ±6% in pig models, while also improving other cardiovascular markers. This was supported by a further journal editorial piece which highlighted the paper’s significance.
2024
November 2022
Alessio Alogna presents inhalation-based approach
Alessio Alogna, one of our founders, presents our inhalation-based approach to treat HFrEF in a large animal model at the American Heart Association’s annual Scientific Sessions event.
October 2022
NanoPhoria publishes research
NanoPhoria publishes research in the Journal of Drug Delivery Science and Technology demonstrating the potency of dry powder inhalation technology.
May 2022
NanoPhoria receives seed funding
NanoPhoria receives €3.5m seed funding from the Sofinnova Telethon Fund
April 2022
NanoPhoria granted patent licences
NanoPhoria granted exclusive patent licences for its Nano-in-Micro, Lung-to-Heart delivery platform, and its therapeutic peptide.
February 2022
NanoPhoria was founded
NanoPhoria was founded by Daniele Catalucci, Michele Iafisco, Alessio Alogna, and Claudio De Luca, as a spin-off from the National Research Council of Italy (CNR).
2022